Last reviewed · How we verify
Conventional fecal microbiota transplantation
Fecal microbiota transplantation restores a healthy gut microbiome by introducing diverse bacterial communities from a donor to treat dysbiosis-related conditions.
Fecal microbiota transplantation restores a healthy gut microbiome by introducing diverse bacterial communities from a donor to treat dysbiosis-related conditions. Used for Clostridioides difficile infection (recurrent or refractory), Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
At a glance
| Generic name | Conventional fecal microbiota transplantation |
|---|---|
| Sponsor | University of Pecs |
| Drug class | Microbiota-based therapeutic |
| Modality | Biologic |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
FMT works by transferring stool from a healthy donor into the gastrointestinal tract of a patient with dysbiosis, reestablishing beneficial microbial populations and their metabolic functions. This restores microbial diversity and competitive exclusion of pathogenic organisms, particularly Clostridioides difficile. The reconstituted microbiota produces short-chain fatty acids and other metabolites that support intestinal barrier function and immune homeostasis.
Approved indications
- Clostridioides difficile infection (recurrent or refractory)
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Common side effects
- Gastrointestinal symptoms (abdominal pain, bloating, diarrhea)
- Fever
- Nausea
- Infection transmission (rare)
Key clinical trials
- Effect of Fecal Microbiota Transplantation (FMT) in Pediatric Functional Gastrointestinal Disorders (NA)
- Study on the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Steroid - Dependent /Steroid-resistant Nephrotic Syndrome in Children (EARLY_PHASE1)
- Fecal Microbiota Transplantation in Patients With Multiple Drug Resistant Klebsiella Pneumoniae Pneumonia (NA)
- Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment (PHASE1)
- The Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment (PHASE2, PHASE3)
- Fecal Filtrate as a Treatment Option of Multiple Recurrent Clostridioides Difficile Infection (PHASE3)
- Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy (NA)
- Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: